When people think of Carl Icahn, people think of his investments with companies such as Apple and Netflix, but lately he’s been active in the upcoming merger of Actavis and Forest Laboratories. What could a move like this mean for big pharma? What could a move like this mean for doctors and patients? Read here and find out. (Source: Steve Brozak, Forbes, 3/4/14).